Invitrogen Developing Engineered hES Cell Lines to Be Used as HTS Platform | GenomeWeb
PHILADELPHIA — Invitrogen is developing human embryonic stem-cell lines that can be used as a high-throughput platform for drug screening, the company said this week.
 
The project is currently in the proof-of-concept stage. If the work is successful, Invitrogen could begin offering services based on the platform toward the end of this year or the beginning of next year, said Jonathan Chesnut, Invitrogen’s director of stem cells and regenerative medicine.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.